Filing Overview
Company: QT Imaging Holdings, Inc. (Nasdaq: QTI). Form: 8-K. Report date: April 3, 2024, with the report filed April 8, 2024. The filing reports entry into definitive agreements with QT Imaging Center, a California sole proprietorship of Dr. John Klock, a member of the Company’s board of directors.
Material Agreements
Data Use and License Agreement
Under the agreement dated April 3, 2024, QT Imaging Holdings received a license to use and disclose certain health information de-identified by QT Imaging Center in accordance with applicable law. The information will support research and analytical activities related to development and commercialization of the QT Ultrasound Breast Scanner-1 and other technologies.
Services Agreement
The Services Agreement is dated April 1, 2024 and was entered into on April 5, 2024. QT Imaging Center will provide healthcare, clinical trial, research and development, clinical validation, training, protocol development and related services.
- Compensation is $450 per hour for services performed by Dr. Klock.
- Services are expected to be provided for a minimum of 15 hours per week as needed, subject to a limit of 60 hours per month unless otherwise agreed.
- The Company states that the compensation represents fair market value and is not based on the volume or value of referrals between the parties.
- QT Imaging Center must submit quarterly reports detailing deliverables and hours worked.
- Payments are due quarterly, generally within 15 business days after the Company receives the applicable report.
- The initial term is one year, with automatic one-year renewals unless terminated.
- The parties agreed to review and potentially revise the terms on July 1, 2024 if either party is dissatisfied.
Financial Metrics and Liquidity
This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, guidance or other financial statement metrics.
Material Changes, Outlook and Risks
The principal reported change is the establishment of a related-party data license and services relationship supporting the Company’s imaging technology development, commercialization and clinical activities. The arrangement creates ongoing service costs and involves a director-affiliated entity. The filing does not provide management guidance or quantify the expected financial impact.
Investor Verification Items
- Review Exhibits 10.1 and 10.2 for the complete scope, termination provisions, data-use rights and other obligations.
- Confirm the amount and timing of payments made or accrued under the Services Agreement.
- Assess the related-party transaction disclosures and the basis for the Company’s fair-market-value determination.
- Monitor the July 1, 2024 review and any amendments or changes to the agreement.
- Evaluate applicable privacy, de-identification, clinical-trial and regulatory requirements governing the licensed health information and related services.